Annual Total Liabilities
$20.39 M
+$19.80 M+3375.84%
30 April 2024
Summary:
PharmaCyte Biotech annual total liabilities is currently $20.39 million, with the most recent change of +$19.80 million (+3375.84%) on 30 April 2024. During the last 3 years, it has risen by +$19.66 million (+2713.09%). PMCB annual total liabilities is now at all-time high.PMCB Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$17.15 M
-$3.24 M-15.87%
31 July 2024
Summary:
PharmaCyte Biotech quarterly total liabilities is currently $17.15 million, with the most recent change of -$3.24 million (-15.87%) on 31 July 2024. Over the past year, it has dropped by -$3.66 million (-17.58%). PMCB quarterly total liabilities is now -23.65% below its all-time high of $22.47 million, reached on 31 January 2024.PMCB Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3375.8% | -17.6% |
| 3 y3 years | +2713.1% | +9117.1% |
| 5 y5 years | +2644.6% | +2033.7% |
PMCB Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +3375.8% | -23.6% | +9117.1% |
| 5 y | 5 years | at high | +3375.8% | -23.6% | +9117.1% |
| alltime | all time | at high | >+9999.0% | -23.6% | >+9999.0% |
PharmaCyte Biotech Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| July 2024 | - | $17.15 M(-15.9%) |
| Apr 2024 | $20.39 M(+3375.8%) | $20.39 M(-9.2%) |
| Jan 2024 | - | $22.47 M(+7.9%) |
| Oct 2023 | - | $20.81 M(+2.0%) |
| July 2023 | - | $20.40 M(+3377.2%) |
| Apr 2023 | $586.60 K(-16.7%) | $586.60 K(-29.1%) |
| Jan 2023 | - | $827.80 K(-36.9%) |
| Oct 2022 | - | $1.31 M(+20.4%) |
| July 2022 | - | $1.09 M(+54.7%) |
| Apr 2022 | $704.40 K(-2.8%) | $704.40 K(+14.9%) |
| Jan 2022 | - | $613.00 K(+229.4%) |
| Oct 2021 | - | $186.10 K(-79.9%) |
| July 2021 | - | $925.00 K(+27.6%) |
| Apr 2021 | $724.80 K(-32.7%) | $724.80 K(+11.7%) |
| Jan 2021 | - | $648.70 K(-2.4%) |
| Oct 2020 | - | $664.70 K(-44.0%) |
| July 2020 | - | $1.19 M(+10.1%) |
| Apr 2020 | $1.08 M(+45.1%) | $1.08 M(+5.8%) |
| Jan 2020 | - | $1.02 M(+26.7%) |
| Oct 2019 | - | $803.90 K(+32.5%) |
| July 2019 | - | $606.60 K(-18.3%) |
| Apr 2019 | $742.90 K(+15.3%) | $742.90 K(+57.7%) |
| Jan 2019 | - | $471.20 K(-28.9%) |
| Oct 2018 | - | $662.40 K(-25.0%) |
| July 2018 | - | $882.90 K(+37.1%) |
| Apr 2018 | $644.20 K(+11.0%) | $644.20 K(-27.4%) |
| Jan 2018 | - | $887.20 K(+56.5%) |
| Oct 2017 | - | $567.00 K(-34.5%) |
| July 2017 | - | $865.70 K(+49.2%) |
| Apr 2017 | $580.20 K(-9.0%) | $580.20 K(+0.3%) |
| Jan 2017 | - | $578.30 K(+28.8%) |
| Oct 2016 | - | $449.00 K(-1.6%) |
| July 2016 | - | $456.50 K(-28.4%) |
| Apr 2016 | $637.60 K(-58.1%) | $637.60 K(-40.2%) |
| Jan 2016 | - | $1.07 M(-1.4%) |
| Oct 2015 | - | $1.08 M(-9.0%) |
| July 2015 | - | $1.19 M(-22.0%) |
| Apr 2015 | $1.52 M(+306.9%) | $1.52 M(+301.7%) |
| Jan 2015 | - | $378.50 K(+36.7%) |
| Oct 2014 | - | $276.90 K(-25.4%) |
| July 2014 | - | $371.40 K(-0.6%) |
| Apr 2014 | $373.70 K | $373.70 K(-22.0%) |
| Jan 2014 | - | $479.30 K(-51.6%) |
| Oct 2013 | - | $991.00 K(-0.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| July 2013 | - | $994.20 K(-73.8%) |
| Apr 2013 | $3.80 M(+0.3%) | $3.80 M(-2.6%) |
| Jan 2013 | - | $3.90 M(-10.8%) |
| Oct 2012 | - | $4.37 M(-5.1%) |
| July 2012 | - | $4.61 M(+21.6%) |
| Apr 2012 | $3.79 M(-4.6%) | $3.79 M(-7.9%) |
| Jan 2012 | - | $4.11 M(+0.3%) |
| Oct 2011 | - | $4.10 M(+3.0%) |
| July 2011 | - | $3.98 M(+0.3%) |
| Apr 2011 | $3.97 M(+8.7%) | $3.97 M(+16.4%) |
| Jan 2011 | - | $3.41 M(+3.0%) |
| Oct 2010 | - | $3.31 M(+1.3%) |
| July 2010 | - | $3.27 M(-10.5%) |
| Apr 2010 | $3.65 M(+25.3%) | $3.65 M(+17.9%) |
| Jan 2010 | - | $3.10 M(+4.8%) |
| Oct 2009 | - | $2.96 M(+3.5%) |
| July 2009 | - | $2.86 M(-2.1%) |
| Apr 2009 | $2.92 M(+1514.6%) | $2.92 M(+2753.2%) |
| Jan 2009 | - | $102.20 K(+26.8%) |
| Oct 2008 | - | $80.60 K(+61.8%) |
| July 2008 | - | $49.80 K(-72.4%) |
| Apr 2008 | $180.60 K(+52.0%) | $180.60 K(+75.0%) |
| Jan 2008 | - | $103.20 K(-2.8%) |
| Oct 2007 | - | $106.20 K(+55.0%) |
| July 2007 | - | $68.50 K(-42.3%) |
| Apr 2007 | $118.80 K(-83.6%) | $118.80 K(-92.5%) |
| Jan 2007 | - | $1.58 M(+106.4%) |
| Oct 2006 | - | $767.00 K(+5.4%) |
| July 2006 | - | $728.00 K(+0.6%) |
| Apr 2006 | $723.90 K(-55.6%) | $723.90 K(-53.5%) |
| Jan 2006 | - | $1.56 M(-11.7%) |
| Oct 2005 | - | $1.76 M(+0.1%) |
| July 2005 | - | $1.76 M(+7.9%) |
| Apr 2005 | $1.63 M(+395.7%) | $1.63 M(-46.9%) |
| Jan 2005 | - | $3.07 M(+1.1%) |
| Oct 2004 | - | $3.04 M(+1.6%) |
| July 2004 | - | $2.99 M(+809.4%) |
| Apr 2004 | $329.10 K(>+9900.0%) | $329.10 K(+245.7%) |
| Jan 2004 | - | $95.20 K(+1600.0%) |
| Oct 2003 | - | $5600.00(+30.2%) |
| July 2003 | - | $4300.00(+72.0%) |
| Apr 2003 | $2500.00(-68.4%) | $2500.00(-71.9%) |
| Jan 2003 | - | $8900.00 |
| Apr 2002 | $7900.00 | - |
FAQ
- What is PharmaCyte Biotech annual total liabilities?
- What is the all time high annual total liabilities for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual total liabilities year-on-year change?
- What is PharmaCyte Biotech quarterly total liabilities?
- What is the all time high quarterly total liabilities for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly total liabilities year-on-year change?
What is PharmaCyte Biotech annual total liabilities?
The current annual total liabilities of PMCB is $20.39 M
What is the all time high annual total liabilities for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual total liabilities is $20.39 M
What is PharmaCyte Biotech annual total liabilities year-on-year change?
Over the past year, PMCB annual total liabilities has changed by +$19.80 M (+3375.84%)
What is PharmaCyte Biotech quarterly total liabilities?
The current quarterly total liabilities of PMCB is $17.15 M
What is the all time high quarterly total liabilities for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly total liabilities is $22.47 M
What is PharmaCyte Biotech quarterly total liabilities year-on-year change?
Over the past year, PMCB quarterly total liabilities has changed by -$3.66 M (-17.58%)